129 related articles for article (PubMed ID: 22782165)
21. [Treatment with infliximab of peristomal pyoderma gangrenosum in ulcerative colitis].
Krag AA; Gjersøe P
Ugeskr Laeger; 2005 May; 167(18):1968-9. PubMed ID: 15929274
[No Abstract] [Full Text] [Related]
22. Severe recalcitrant pyoderma gangrenosum treated with infliximab.
Kaur MR; Lewis HM
Br J Dermatol; 2005 Sep; 153(3):689-91. PubMed ID: 16120178
[No Abstract] [Full Text] [Related]
23. Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis.
Teich N; Klugmann T
J Crohns Colitis; 2014 Jan; 8(1):85-6. PubMed ID: 23810275
[No Abstract] [Full Text] [Related]
24. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
Tanczos BT; Baumgart DC
Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
[No Abstract] [Full Text] [Related]
25. Refractory pyoderma gangrenosum associated with ulcerative colitis successfully treated with infliximab.
Ueda M; Katoh M; Tanizaki H; Tanioka M; Matsumura Y; Miyachi Y
Dermatol Online J; 2012 Jan; 18(1):12. PubMed ID: 22301049
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of recalcitrant pyoderma gangrenosum with infliximab complicated by tuberculosis despite negative screening tests.
Uthman I; El-Sayad J; Sharara A
Clin Exp Dermatol; 2005 May; 30(3):294. PubMed ID: 15807693
[No Abstract] [Full Text] [Related]
27. Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis.
Tada M; Nakanishi T; Hirata C; Okano T; Sugioka Y; Wakitani S; Nakamura H; Koike T
Mod Rheumatol; 2010 Dec; 20(6):598-601. PubMed ID: 20680379
[TBL] [Abstract][Full Text] [Related]
28. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy.
Bruzzese V
J Clin Rheumatol; 2012 Dec; 18(8):413-5. PubMed ID: 23188209
[TBL] [Abstract][Full Text] [Related]
29. Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis.
Ermis F; Ozdil S; Akyüz F; Pinarbasi B; Mungan Z
Inflamm Bowel Dis; 2008 Nov; 14(11):1611-3. PubMed ID: 18401859
[No Abstract] [Full Text] [Related]
30. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?
Adişen E; Oztaş M; Gürer MA
Dermatology; 2008; 216(2):163-5. PubMed ID: 18216480
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases.
Cocco A; Angelucci E; Viscido A; Caprilli R
Inflamm Bowel Dis; 2007 Oct; 13(10):1317-9. PubMed ID: 17508417
[No Abstract] [Full Text] [Related]
32. Pyoderma gangrenosum solved by ustekinumab therapy.
López González J; Lázaro Sáez M; Moreno Moraleda I; Hernández Martínez Á
Gastroenterol Hepatol; 2021 Apr; 44(4):299-300. PubMed ID: 33069432
[No Abstract] [Full Text] [Related]
33. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody).
Jenne L; Sauter B; Thumann P; Hertl M; Schuler G
Br J Dermatol; 2004 Feb; 150(2):380-2. PubMed ID: 14996124
[No Abstract] [Full Text] [Related]
34. Superficial pyoderma gangrenosum treated with infliximab: a case report.
Bhatti H; Khalid N; Rao B
Cutis; 2012 Dec; 90(6):297-9. PubMed ID: 23409478
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
36. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
[TBL] [Abstract][Full Text] [Related]
37. A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab.
Donmez S; Pamuk ON; Gedik M; A K R; Bulut G
Int J Rheum Dis; 2014 May; 17(4):471-5. PubMed ID: 24460826
[TBL] [Abstract][Full Text] [Related]
38. [Utility of infliximab in gangrenous pyoderma not associated with inflammatory bowel disease].
Pérez-De Pedro I; Gómez-Moyano E; López-Carmona D; Muñoz-Roca NL; De Ramón-Garrido E; Camps-García MT
Rev Clin Esp; 2010; 210(7):367-9. PubMed ID: 20466360
[No Abstract] [Full Text] [Related]
39. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum.
Greb JE; Gottlieb AB; Goldminz AM
Dermatol Ther; 2016 Nov; 29(6):482-483. PubMed ID: 27502191
[No Abstract] [Full Text] [Related]
40. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
Reddick CL; Singh MN; Chalmers RJ
Dermatol Online J; 2010 Aug; 16(8):15. PubMed ID: 20804692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
